Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: The CARDIA Study

European Journal of Preventive Cardiology

Volumn 14, Issue 2, 2007, Pages 222-229

  Iribarren, Carlos ^a   Husson, Gail ^a   Sydow, Karsten ^b   Wang, Bing Yin ^b   Sidney, Stephen ^a   Cooke, John P ^b  

^a DIVISION OF RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

asymmetric dimethylarginine; atherosclerosis; endothelial dysfunction; risk factors; young adults

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTERY CALCIFICATION; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; UNITED STATES; WAIST CIRCUMFERENCE;

ADULT; ANALYSIS OF VARIANCE; ARGININE; BIOLOGICAL MARKERS; CALCINOSIS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; RESEARCH DESIGN; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34247548465     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000230108.86147.40     Document Type: Article

References (49)

1. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 1986; 58: 552–564.
2. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228–234.
3. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997; 30: 325–333.
4. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 (Suppl 12):S60–S62.
5. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542–548.
6. Böger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847.
7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575.
8. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652–658.
9. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, Arnold JM. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 1998; 37: 667–675.
10. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068–2074.
11. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 1998; 77: 808–813.
12. Maas R, Schwedhelm E, Albsmeier J, Böger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002; 7: 213–225.
13. Kielstein JT, Böger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594–600.
14. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, et al. Overexpression of dimethylarginine imethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111: 1431–1438.
15. Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420–1426.
16. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127–2128.
17. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141–1146.
18. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425–430.
19. Takiuchi S, Fujii H, Kamide K, Horio T, Nakatani S, Hiuge A, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004; 17: 802–808.
20. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: e53–e59.
21. Hughes GH, Cutter G, Donahue R, Friedman GD, Hulley S, Hunkeler E, et al. Recruitment in the Coronary Artery Disease Risk Development in Young Adults (CARDIA) Study. Control Clin Trials 1987; 8 (Suppl 4):S68–S73.
22. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: Study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41: 1105–1116.
23. Dyer AR, Cutter GR, Liu KQ, Armstrong MA, Friedman GD, Hughes GH, et al. Alcohol intake and blood pressure in young adults: the CARDIA Study. J Clin Epidemiol 1990; 43: 1–13.
24. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. In: Albers JJ, Segrest JP, editors. Methods of enzymology, Vol. 129:101B122. New York: Academic Press, Inc.; 1986.
25. Warnick GR, Benderson JM, Albers JJ, Baillie EE, Sexton B, Schaefer EJ, et al. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379–1388.
26. Friedewald WT, Levy RI, Fredrikson DS. Estimation of the concentration of the low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
27. Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, et al. Cardiovascular risk factors in young adults. The CARDIA baseline monograph. Control Clin Trials 1991; 12 (Suppl 1):1S–77S.
28. Slein MW, Cori GT, Cori CF. A comparative study of hexokinase from yeast and animal tissues. J Biol Chem 1950; 186: 763–780.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
30. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136–2141.
31. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000; 11: 155A.
32. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH. Determination of asymmetric dimethylarginine (ADMA) by a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377–1383.
33. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–832.
34. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 2005; 234: 35–43.
35. Huang PH, Chen LC, Leu HB, Ding PY, Chen JW, Wu TC, Lin SJ. Enhanced coronary calcification determined by electron beam CT is strongly related to endothelial dysfunction in patients with suspected coronary artery disease. Chest 2005; 128: 810–815.
36. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an ‘uraemic toxin’ to a global cardiovascular risk molecule. Eur J Clin Invest 2005; 35: 71–79.
37. Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA 1996; 276: 1186–1188.
38. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol 2004; 20 (Suppl B):7B–15B.
39. Stühlinger MC, Tsao PS, Her J-H, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the NO synthase pathway — role of asymmetric dimethylarginine. Circulation 2001; 104: 2569–2575.
40. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987–992.
41. Baylis C. Nitric oxide deficiency in chronic renal disease. Eur J Clin Pharmacol 26 October 2005; 1–8. E-pub ahead of print.
42. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 2004; 89: 6277–6281.
43. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 1996; 94: 1175–1192.
44. Kennedy J, Shavelle R, Wang S, Budoff M, Detrano RC. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. Am Heart J 1998; 135: 696–702.
45. Secci A, Wong N, Tang W, Wang S, Doherty T, Detrano R. Electron beam computed tomographic coronary calcium as a predictor of coronary events: comparison of two protocols. Circulation 1997; 96: 1122–1129.
46. Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003; 107: 2571–2576.
47. Cheng YJ, Church TS, Kimball TE, Nichaman MZ, Levine BD, McGuire DK, Blair SN. Comparison of coronary artery calcium detected by electron beam tomography in patients with to those without symptomatic coronary heart disease. Am J Cardiol 2003; 92: 498–503.
48. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 2004; 110: 3424–3429.
49. Valtonen P, Karppi J, Nyyssonen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 828: 97–102